Ty-Jour T1 - 人类肺部修复的潜在治疗靶标 exvivo 肺灌注JF - 欧洲呼吸期刊Jo - Eur Respir J Do - 10.1183 / 13993003.02222-2019 VL - 55 IS - 4 SP - 1902222Au - Wong，Aaron Au - Zamel，Ricardo Au - Yeung，Jonathan Au - Bader，Gary D. Au - Dos Santos，Claudia C. Au - Bai，Xiaohui Au - Wang，Yubo Au - Keshavjee，Shaf Au - Liu，MingyaoY1 - 2020/04/01 UR - //www.qdcxjkg.com/content/55/4/1902222.Abstract n2 - 简介EXVivo肺灌注（EVLP）技术已经开发出来评估边缘供体的功能肺部并显着增加了供体肺利用率。EVLP还通过伤害特异性治疗（如抗生素或纤维蛋白溶解剂）探索为供体肺修复的平台。我们假设移植和EVLP之间共享的积极表达途径可以揭示移植前肺部修复损伤和潜在治疗靶标的常见机制。通过“脑死后捐赠后捐赠”肺部的外周组织活组织检查进行回顾性转录组织分析。46预移植后/后/后/后evlp对。途径分析用于鉴定和比较供体肺部移植和eVLP的反应。结果22途径主要富集移植，包括淋巴细胞活化和细胞死亡的上调和代谢下调。八种途径主要在EVLP中富集，包括下调白细胞功能和血管过程的上调。常规富集27种途径，包括激活先天炎症，细胞死亡，热应激和代谢和蛋白质合成的下调。 Of the inflammatory clusters, Toll-like receptor/innate immune signal transduction adaptor signalling had the greatest number of nodes and was central to inflammation. These mechanisms have been previously speculated as major mechanisms of acute lung injury in animal models.Conclusion EVLP and transplantation share common molecular features of injury including innate inflammation and cell death. Blocking these pathways during EVLP may allow for lung repair prior to transplantation.Inflammation and cell death pathways are common molecular features of ischaemia–reperfusion and ischaemia–ex vivo lung perfusion. These may represent therapeutic targets for lung repair prior to transplantation. http://bit.ly/2sIrxOP ER -